Evidence map›Paper›PMID 29186841›Full record

ArticleInternational journal of molecular sciences2017

Synthetic Secoisolariciresinol Diglucoside (LGM2605) Protects Human Lung in an Ex Vivo Model of Proton Radiation Damage.

Anastasia Velalopoulou, Shampa Chatterjee, Ralph A Pietrofesa, Cynthia Koziol-White, Reynold A Panettieri, Liyong Lin, Stephen Tuttle, Abigail Berman, Constantinos Koumenis, Melpo Christofidou-Solomidou

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Oxidative Stress and Space Biology: An Organ-Based Approach.International journal of molecular sciences · 2018
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Anastasia VelalopoulouDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania Perelman School of Medicine, 3450 Hamilton Walk, Stemmler Hall, Office Suite 227, Philadelphia, PA 19104, USA. avelalopoulou@gmail.com.
Shampa ChatterjeeDepartment of Physiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. shampac@pennmedicine.upenn.edu.
Ralph A PietrofesaDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania Perelman School of Medicine, 3450 Hamilton Walk, Stemmler Hall, Office Suite 227, Philadelphia, PA 19104, USA. ralphp@pennmedicine.upenn.edu.
Cynthia Koziol-WhiteDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania Perelman School of Medicine, 3450 Hamilton Walk, Stemmler Hall, Office Suite 227, Philadelphia, PA 19104, USA. cjk167@rbhs.rutgers.edu.
Reynold A PanettieriDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania Perelman School of Medicine, 3450 Hamilton Walk, Stemmler Hall, Office Suite 227, Philadelphia, PA 19104, USA. rp856@rbhs.rutgers.edu.
Liyong LinDepartment of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. Liyong.Lin@uphs.upenn.edu.
Stephen TuttleDepartment of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. Steve.Tuttle@uphs.upenn.edu.
Abigail BermanDepartment of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. abigail.berman@uphs.upenn.edu.
Constantinos KoumenisDepartment of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. Costas.Koumenis@uphs.upenn.edu.
Melpo Christofidou-SolomidouDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania Perelman School of Medicine, 3450 Hamilton Walk, Stemmler Hall, Office Suite 227, Philadelphia, PA 19104, USA. melpo@pennmedicine.upenn.edu.
University of Pennsylvania · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI A. Clementina Mesaros · 2006 to 2026
$35.3M
Environmental Science Project 3 - Social Determinants of Risk and Attitudes AboutP42ES023720 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI BLAIR, IAN ALEXANDER · 2014 to 2018
$11.3M
Secoisolariciresinol Diglucoside (SDB) Protection in Radiation PheumonopathyR01CA133470 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHRISTOFIDOU-SOLOMIDOU, MELPO · 2008 to 2012
$2.2M
NOVEL SYNTHETIC SDG TO TREAT TRAUMA-INDUCED INFLAMMATIONR21AT008291 · NCCIH · UNIVERSITY OF PENNSYLVANIA · PI CHRISTOFIDOU-SOLOMIDOU, MELPO, WINKELSTEIN, BETH A · 2015 to 2016
$440k
Piperlongumine as a Novel Radiosensitizer for Lung CancerR21CA178654 · NCI · NORTH DAKOTA STATE UNIVERSITY · PI CHRISTOFIDOU-SOLOMIDOU, MELPO, REINDL, KATIE · 2015 to 2016
$379k
Mesothelioma inhibition by secoisolariciresinol diglucoside (SDG)R03CA180548 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHRISTOFIDOU-SOLOMIDOU, MELPO · 2013 to 2014
$137k
NCCIH NIH HHS R21 AT008291NCI NIH HHS R01 CA133470NCI NIH HHS R03 CA180548NCI NIH HHS R21 CA178654NIEHS NIH HHS P30 ES013508NIEHS NIH HHS P42 ES023720
6 · The paper itself

Abstract

Radiation therapy for the treatment of thoracic malignancies has improved significantly by directing of the proton beam in higher doses on the targeted tumor while normal tissues around the tumor receive much lower doses. Nevertheless, exposure of normal tissues to protons is known to pose a substantial risk in long-term survivors, as confirmed by our work in space-relevant exposures of murine lungs to proton radiation. Thus, radioprotective strategies are being sought. We established that LGM2605 is a potent protector from radiation-induced lung toxicity and aimed in the current study to extend the initial findings of space-relevant, proton radiation-associated late lung damage in mice by looking at acute changes in human lung. We used an ex vivo model of organ culture where tissue slices of donor living human lung were kept in culture and exposed to proton radiation. We exposed donor human lung precision-cut lung sections (huPCLS), pretreated with LGM2605, to 4 Gy proton radiation and evaluated them 30 min and 24 h later for gene expression changes relevant to inflammation, oxidative stress, and cell cycle arrest, and determined radiation-induced senescence, inflammation, and oxidative tissue damage. We identified an LGM2605-mediated reduction of proton radiation-induced cellular senescence and associated cell cycle changes, an associated proinflammatory phenotype, and associated oxidative tissue damage. This is a first report on the effects of proton radiation and of the radioprotective properties of LGM2605 on human lung.

Indexed as

Anti-Inflammatory AgentsButylene GlycolsCell Cycle CheckpointsCellular SenescenceGlucosidesHumansLungOxidative StressProtonsRadiation PneumonitisRadiation-Protective AgentsAnti-Inflammatory AgentsButylene GlycolsGlucosidesProtonsRadiation-Protective Agentssecoisolariciresinol diglucosideantioxidantcell cyclehuman lung sectionsinflammationLGM2605organ cultureoxidative stressphase II enzymesproton radiationreactive oxygen speciessenescence

Identifiers

PMID29186841
PMCPMC5751128
OpenAlexW2769972663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.